| The epidemiology and genetics of hyperuricemia and gout across major racial groups: a literature review and population genetics secondary database analysis F Butler, A Alghubayshi, Y Roman Journal of personalized medicine 11 (3), 231, 2021 | 79 | 2021 |
| The Daniel K. Inouye College of Pharmacy Scripts: perspectives on the epidemiology of gout and hyperuricemia YM Roman Hawai'i Journal of Medicine & Public Health 78 (2), 71, 2019 | 46 | 2019 |
| Assessment of genetic polymorphisms associated with hyperuricemia or gout in the Hmong YM Roman, KA Culhane-Pera, J Menk, RJ Straka Personalized medicine 13 (5), 429-440, 2016 | 35 | 2016 |
| Engaging Hmong adults in genomic and pharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach KA Culhane-Pera, RJ Straka, MK Moua, Y Roman, P Vue, K Xiaaj, MX Lo, ... Journal of community genetics 8, 117-125, 2017 | 33 | 2017 |
| The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort Y Roman, M Tiirikainen, E Prom-Wormley Clinical rheumatology 39, 2387-2392, 2020 | 25 | 2020 |
| The United States 2020 Census data: implications for precision medicine and the research landscape Y Roman Personalized Medicine 19 (1), 5-8, 2022 | 22 | 2022 |
| Health disparities of cardiometabolic disorders among Filipino Americans: implications for health equity and community-based genetic research G Coronado, J Chio-Lauri, RD Cruz, YM Roman Journal of racial and ethnic health disparities, 1-8, 2021 | 21 | 2021 |
| Genetic assessment of hyperuricemia and gout in Asian, Native Hawaiian, and Pacific Islander subgroups of pregnant women: biospecimens repository cross-sectional study A Alghubayshi, A Edelman, K Alrajeh, Y Roman BMC rheumatology 6, 1-13, 2022 | 20 | 2022 |
| Gout prevalence in the Hmong: a prime example of health disparity and the role of community-based genetic research YM Roman, K Lor, T Xiong, K Culhane-Pera, RJ Straka Personalized Medicine 18 (3), 311-327, 2021 | 17 | 2021 |
| Race and precision medicine: is it time for an upgrade YM Roman Pharmacogenomics J 19 (1), 1-4, 2019 | 14 | 2019 |
| Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation YM Roman, DL Dixon, TM Salgado, ET Price, KM Zimmerman, L Sargent, ... Pharmacogenomics 21 (9), 627-635, 2020 | 12 | 2020 |
| The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups KY Alrajeh, YM Roman Personalized Medicine 19 (4), 327-339, 2022 | 10 | 2022 |
| Moving the needle in gout management: the role of culture, diet, genetics, and personalized patient care practices YM Roman Nutrients 14 (17), 3590, 2022 | 9 | 2022 |
| THE IMPACT OF RS505802 FOR SLC22A12 ON OXIPURINOL AND URIC ACID DISPOSITION IN HMONG PATIENTS ON ALLOPURINOL FROM THE GENETICS OF HYPERURICEMIA THERAPY IN HMONG (GOUTH) STUDY. YM Roman, KA Culhane-Pera, MC Lo, S Yang, J Yang, M Lo, RJ Straka Clinical pharmacology & therapeutics 101 (S 1), S48-S48, 2017 | 9 | 2017 |
| Pharmacogenetic perspective for optimal gout management KY Alrajeh, YM Roman Future Pharmacology 2 (2), 135-152, 2022 | 8 | 2022 |
| Cardiometabolic genomics and pharmacogenomics investigations in Filipino Americans: steps towards precision health and reducing health disparities YM Roman, D McClish, ET Price, RT Sabo, OM Woodward, TB Mersha, ... American heart journal plus: cardiology research and practice 15, 100136, 2022 | 8 | 2022 |
| The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing O AlAzzeh, Y M Roman Pharmacogenomics 24 (3), 173-182, 2023 | 6 | 2023 |
| The frequency of rs2231142 in ABCG2 among Asian subgroups: implications for personalized rosuvastatin dosing K Alrajeh, YM Roman Pharmacogenomics 24 (1), 15-26, 2023 | 6 | 2023 |
| Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White Paper A Mitra, MA Ahmed, R Krishna, K Sun, FD Gibbons, O Campagne, ... Clinical Pharmacology & Therapeutics 114 (3), 515-529, 2023 | 5 | 2023 |
| HLA-B* 58: 01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinol K Peng, J Bjork, YF Wen, YM Roman, K Culhane-Pera, MX Lo, E Gertner, ... Pharmacogenetics and genomics 30 (2), 21-25, 2020 | 5 | 2020 |
